Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis

BACKGROUND: Although low-molecular-weight heparin (LMWH) is recommended as the first-line treatment in patients with active cancer and venous thromboembolism (VTE), many patients are more willing to choose oral anticoagulants. We collected currently available data to evaluate the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Jiali, Yin, Xiangbao, Chen, Desheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081055/
https://www.ncbi.nlm.nih.gov/pubmed/30075504
http://dx.doi.org/10.1097/MD.0000000000011384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081055/
https://www.ncbi.nlm.nih.gov/pubmed/30075504
http://dx.doi.org/10.1097/MD.0000000000011384

Ejemplares similares